Latest SMS Lifesciences India Ltd (SMSLIFE:NSI) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
SMS Lifesciences India的摊薄每股收益复合年均增长率(持续经营的业务)(10年)无意义。在计算变动时,我们检测到最新值是负值,导致计算已无意义。. 查看SMS Lifesciences India Ltd的摊薄每股收益复合年均增长率(持续经营的业务)(10年)趋势、图表等
过去5年,SMS Lifesciences India的epv调整后盈利在March 2022达到了 234.9百万的峰值。 SMS Lifesciences India的epv调整后盈利于March 2021触及5年低点,是177.4百万。 SMS Lifesciences India的epv调整后盈利于2020 (180.1百万, -24.6%)、2021 (177.4百万, -1.5%)、2023 (200.6百万, -14.6%)和2024 (188百万, ...
Truist Financial Lowers ICON Public (NASDAQ:ICLR) Price Target to $262.00 14 Feb 2025 22:56:11By Buzz FX IAC (NASDAQ:IAC) Price Target Cut to $76.00 by Analysts at Truist Financial 14 Feb 2025 22:56:11By Buzz FX Western Energy Services Corp. (OTCMKTS:WEEEF) Short Interest Down 52.2%...
SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The firm's products include pharmaceutical ingredients and intermediaries. The company was founded on May 31, 2006 and is headquartered in Hyderabad, India. VALUATION P/E Current 41.13 P/E Ratio (...
North America (USA, Canada) East Asia (e.g. China, Japan, Korea) Europe - EU countries Europe - non EU (e.g. UK, Russia, ex-CIS countries) South East Asia (e.g. Thailand, Philippines, Singapore) SMS Life sciences India Limited ...
供应商信息 企业名称 SMS LIFESCIENCES INDIa LIMITED,UNIT-IV 备注 若未能联系上供应商,可在药智通发布求购信息(https://s.yaozh.com/Purchase/release),或联系药智通客服17318480790(微信同号) 扩展信息 VIP试用医疗器械查询APP下载客服中心常见问题数据可视化数据分析挖掘系统网站地图业务介绍友情链接 ...
SMS Lifesciences India的摊薄每股收益累计增长率(5年)是-49.1%. 查看SMS Lifesciences India Ltd的摊薄每股收益累计增长率(5年)趋势、图表等
以下为SMS Lifesciences India Ltd每股AFFO的一致预期均值数据要点 1 31, 2025: - 表现汇总 指标使用情况:每股AFFO的一致预期均值 隐藏这个小工具 Slug affo_share_proj_mean_raw 数据类型 数目 格式 文字 默认期限 当期 支持的期限 FY, Q 套餐 免费
SMS Lifesciences India的ev/最近12个月ebitda减资本支出于March 2020触及5年低点,是3.4x。 SMS Lifesciences India的ev/最近12个月ebitda减资本支出于2020 (3.4x, -49.9%)、2022 (8.1x, -1.9%)和2023 (7.5x, -8.3%)减少和于2021 (8.3x, +140.9%)和2024 (17.5x, +135.1%)增加。